2nd Annual Global Business Intelligence Summit

eyeforpharmaMarch 18-19, 2009, Nassau Inn, Princeton, New Jersey, USA.
Pharma & Biotech companies seeking competitive advantage are now relying on BI as an innovation and decision-making driver. Innovative strategies offer the possibility of transforming insight into action, of making decisions quickly, and capitalizing on opportunities more fully.

eyeforpharma's 2nd Annual Global Business Intelligence Summit will provide you with the latest industry intelligence on the areas that matter most, including: The Drug Pipeline, Emerging Markets, Integration of Intelligence Functions along with exclusive tips on how to overcome the current economic downturn, The conference will also look in-depth at Competitive Intelligence, tackling issues such as the Ethics of CI, Developing a CI Culture plus primary research advice.

This event guarantees insightful conclusions and takeaway messages for the senior-level pharma audience it will attract. Here is a brief overview of what it the Summit will examine

  • Strategic Overview of Intelligence in 2009 and beyond: Strategies and tactics to ensure how you can safeguard your company from the economic climate, How you can prepare yourself for the impact of US elections on the industry plus a look at payor models all over the world
  • Competitive Intelligence: Understand how the industry is navigating the ethics of CI, learn who is building and integrating a CI function throughout it's business and what they hope to achieve through this and analyse the latest techniques in primary research for today and the future
  • Emerging Markets: Examine what is truly happening in the key emerging markets and what established can learn from them and how we can avoid the minefield of expanding into them
  • Marketing Intelligence: Analyze what your customers want from you! Hear from Forecasters and other pharma functions about how to help them understand and deliver smarter decisions faster!
  • Cross Functional Excellence: Unite data analyses from marketing research, sales analytics, marketing analytics, competitive intelligence, forecasting to drive big picture business decisions
  • IT, Data & Analytics: Discover the best ways to manage primary and secondary vendors and discover the answer to a critical questions: Centralise or De-Centralise Intelligence

For further information and registration, please visit:
http://www.eyeforpharma.com/gbi/

About eyeforpharma
eyeforpharma is a leading global source of information for the pharmaceutical industry. Our reputation has been built on quality, in-depth conferences that have distinguished themselves from competitors by the depth and breadth of research we put into each conference to ensure it is covering the hottest and most pertinent issues of the industry. Months are spent talking directly to senior executives in the industry, as well as relevant consultants and journalists and well respected solutions providers. For more information, please visit www.eyeforpharma.com.

Most Popular Now

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...